Achieve Life Sciences will announce its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The company is focused on developing cytisinicline, a plant-based drug aimed at treating nicotine dependence for smoking and vaping cessation. Cytisinicline's New Drug Application was accepted by the FDA in September 2025, with a review deadline set for June 20, 2026. This drug addresses a significant public health need, as millions of adults in the U.S. smoke or vape, and there are currently no FDA-approved treatments specifically for e-cigarette cessation.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
